Compare IDEXX Laboratories, Inc. (IDXX) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Macy's Inc — how do they compare? IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B), while Macy's Inc trades at $22.7 (market cap $5.95B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.8× Macy's Inc's market cap, and Macy's Inc pays a 3.36% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Macy's Inc for 58 Days on average.
| IDXX | M | |
|---|---|---|
Market Cap | $40.43B | $5.95B |
Volume | 692,164 | 6,030,644 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $26.21 |
52-Week Low | $504.70 | $16.51 |
Typical Hold Time | 46 Days | 58 Days |
Enterprise Value | $41.32B | $9.75B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Macy's stock trades at $22.61, down 0.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and a 'Bold New Chapter' strategy driving digital transformation. Valuation metrics appear attractive with P/E of 8.35 and P/S of 0.27, while profitability shows recovery with ROE of 15.99% and net margin improvement to 3.29%.
The outlook remains cautiously optimistic with analyst consensus at $24.25 representing 7% upside potential. Key opportunities include digital growth initiatives and dividend sustainability, while risks involve retail sector headwinds and uneven quarterly performance. The stock offers value characteristics with turnaround potential, supported by improved cash flow generation and balance sheet strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
